SCHEMBL25877912

SCHEMBL25877912

Cc1cc(C(=O)O)c(F)c(OCc2ccccc2)c1OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 1/20 0.48
MCL1 Q07820 1/20 0.47
BRD4 O60885 1/20 0.46
FFAR4 Q5NUL3 1/20 0.46
PTPN1 P18031 1/20 0.46
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
MRGPRX4 Q96LA9 5/20 0.45
FOLH1 Q04609 1/20 0.45
CTSV O60911 1/20 0.44
CTSL P07711 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
RXRA P19793 1/20 0.43
RXRB P28702 1/20 0.43
RXRG P48443 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27678664 0.87 PTGER1 (0.51) PTGER1MCL1FFAR4PTPN1LMNA
SCHEMBL14882664 0.85 CTSV (0.52) PTGER1MCL1BRD4FFAR4LMNA
SCHEMBL30141095 0.84 FOLH1 (0.52) PTGER1MCL1MRGPRX4FOLH1CTSV
SCHEMBL6761323 0.84 FOLH1 (0.52) PTGER1MCL1MRGPRX4FOLH1CTSV
SCHEMBL24983696 0.84 LMNA (0.54) MCL1BRD4PTPN1LMNAHPGD
SCHEMBL27720163 0.83 CTSV (0.51) BRD4LMNAHPGDMRGPRX4FOLH1
SCHEMBL24140919 0.83 MRGPRX4 (0.51) LMNAHPGDMRGPRX4FOLH1CTSV
SCHEMBL12379065 0.82 PTGER1 (0.53) PTGER1MCL1FFAR4PTPN1LMNA
SCHEMBL9617336 0.82 MAPT (0.52) PTGER1MCL1BRD4LMNAHPGD
SCHEMBL28322588 0.80 MRGPRX4 (0.48) PTGER1MCL1FFAR4PTPN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF TEMPEST THERAPEUTICS, INC. 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234943-A1 TREX1 INHIBITORS AND USES THEREOF FEN1, ERCC4, DCLRE1B PTGER1 1918/4885MCL1 1660/4885BRD4 1515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.